Curis, Inc. (CRIS) Announces Abstracts For Its Partnered Programs, Erivedge(R) And Debio 0932 To Be Presented At The 2014 American Society of Clinical Oncology Annual Meeting
5/23/2014 10:18:09 AM
LEXINGTON, Mass., May 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that its collaborators, Roche/Genentech and Debiopharm Group™ will present results from clinical studies of Erivedge® and Debio 0932, respectively, at the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) to be held from May 30th to June 3rd in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by